泽璟制药-U
(688266)
| 流通市值：145.85亿 | | | 总市值：145.85亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 108,244,408.58 | 386,438,784.02 | 282,104,804.49 | 219,928,154.33 |
| 营业收入 | 108,244,408.58 | 386,438,784.02 | 282,104,804.49 | 219,928,154.33 |
| 二、营业总成本 | 158,939,244.62 | 778,740,484.69 | 541,758,673.77 | 358,131,612.47 |
| 营业成本 | 7,149,214.53 | 29,212,095.95 | 21,449,337.73 | 16,489,388.28 |
| 税金及附加 | 235,709.79 | 1,023,163.55 | 716,056.01 | 488,991.85 |
| 销售费用 | 60,109,621.6 | 250,488,357.76 | 172,193,131.08 | 117,644,761.96 |
| 管理费用 | 14,058,987.04 | 16,560,957.75 | 21,708,376.71 | 6,471,436.19 |
| 研发费用 | 84,346,541.11 | 496,329,685.86 | 335,190,822.91 | 220,319,327.87 |
| 财务费用 | -6,960,829.45 | -14,873,776.18 | -9,499,050.67 | -3,282,293.68 |
| 其中:利息费用 | 7,012,285.59 | 22,552,728.97 | 16,308,154.57 | 10,306,099.32 |
| 其中:利息收入 | 14,516,923.48 | 39,354,994.8 | 27,153,784.16 | 14,353,635.82 |
| 加:公允价值变动收益 | 2,481,810.54 | 8,725,963.9 | 7,794,419.12 | 2,429,032.66 |
| 加:投资收益 | 505,946.82 | 5,958,525.53 | 1,528,842.1 | 1,528,841.37 |
| 信用减值损失(新) | -572,773.26 | -1,619,378.03 | -1,015,098.48 | -1,977,320.65 |
| 其他收益 | 2,655,577.65 | 81,454,190.94 | 34,978,075.76 | 14,062,036.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -45,624,274.29 | -297,782,398.33 | -216,367,630.78 | -122,160,868.74 |
| 加:营业外收入 | 442.48 | 4,955.76 | 4,955.76 | 2,477.88 |
| 减:营业外支出 | - | 1,307,069.11 | 904,975.23 | 583,961.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -45,623,831.81 | -299,084,511.68 | -217,267,650.25 | -122,742,352.09 |
| 减:所得税费用 | -993,045.91 | -3,949,557.69 | -2,971,514.11 | -1,939,595.2 |
| 六、净利润 | -44,630,785.9 | -295,134,953.99 | -214,296,136.14 | -120,802,756.89 |
| 持续经营净利润 | -44,630,785.9 | -295,134,953.99 | -214,296,136.14 | -120,802,756.89 |
| 归属于母公司股东的净利润 | -39,499,383.01 | -278,582,744.17 | -202,089,409.77 | -114,228,726.64 |
| 少数股东损益 | -5,131,402.89 | -16,552,209.82 | -12,206,726.37 | -6,574,030.25 |
| (一)基本每股收益 | -0.15 | -1.09 | -0.8 | -0.46 |
| (二)稀释每股收益 | -0.15 | -1.09 | -0.8 | -0.46 |
| 八、其他综合收益 | 104,914.23 | -2,670,887.43 | 2,096,126.56 | 2,588,560.46 |
| 归属于母公司股东的其他综合收益 | 79,994.91 | -3,108,162.47 | 1,403,393.62 | 1,668,389.19 |
| 九、综合收益总额 | -44,525,871.67 | -297,805,841.42 | -212,200,009.58 | -118,214,196.43 |
| 归属于母公司股东的综合收益总额 | -39,419,388.1 | -281,690,906.64 | -200,686,016.15 | -112,560,337.45 |
| 归属于少数股东的综合收益总额 | -5,106,483.57 | -16,114,934.78 | -11,513,993.43 | -5,653,858.98 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-28 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |